Infographic
Single Drug Assessments in Lung Cancer
2011年肺癌的SDA出版 - 2022年7月
2022年8月4日
下载

The Health Technology Assessment (HTA) Accelerator from IQVIA lets you analyze past and current payer assessments and evidence requirements to guide clinical trial design and market access strategy across the product lifecycle. Analyze the numbers of Single drug assessments in Lung cancer from January 2011 till July 2022. If you need more detailed analysis, request your trial access: //m.kurtisdurfey.com/form-pages/demo

相关解决方案